Letter to Shareholders from Sean Carrick
Dear Shareholder, The past eighteen months have been a challenging time for Nascent Biotech. After successfully completing Phase I establishing safety at multiple ascending cohorts and showing [...]
Pritumumab is a proprietary monoclonal antibody (mAb) targeting a novel antigen on cancer cells.
Pritumumab has received FDA orphan drug status
NASCENT BIOTECH NEWS
